TNFRSF17 and Miyoshi myopathy: Belantamab mafodotin is a first-in-class ADC that binds to BCMA on the surface of MM cells, targeting them for elimination via a multimodal mechanism including apoptosis, antibody-dependent cellular cytotoxicity, and phagocytosis [3, 4].